What is the recommended way to administer methotrexate in the Capizzi regimen for a patient ≤30 years old with acute lymphoblastic leukaemia undergoing interim‑maintenance therapy who has normal renal and hepatic function?

Capizzi Methotrexate Administration in ALL Interim Maintenance

In the Capizzi regimen for patients ≤30 years with acute lymphoblastic leukemia during interim maintenance, methotrexate is administered intravenously at escalating doses starting at 100 mg/m² and increasing weekly to a maximum of 1000 mg/m², given as a loading dose over 30 minutes followed by the remainder over 23.5 hours, with NO leucovorin rescue, and accompanied by PEG-asparaginase 2500 units/m² intramuscularly 24 hours after methotrexate completion. 1

Dosing Schedule and Administration

• Start with 100 mg/m² IV and escalate weekly by increments (typically 50-100 mg/m²) up to a target of 1000 mg/m² over approximately 10 weeks 1, 2
• The infusion is given over 24 hours total: 10% as a loading dose over 30 minutes, then the remaining 90% over 23.5 hours 3
• This occurs during the interim maintenance phase (8 weeks) following consolidation therapy 1

Critical Distinguishing Feature: No Leucovorin Rescue

• The Capizzi regimen specifically omits leucovorin rescue, which is the key difference from high-dose methotrexate protocols 4
• This absence of rescue puts patients at higher risk for multiorgan toxicity, even at intermediate doses 4
• If severe toxicity develops (pancytopenia, mucositis, dermatologic toxicity), immediately administer high-dose leucovorin 10 mg/m² every 6 hours until toxicity resolves 4

Asparaginase Component

• PEG-asparaginase 2500 units/m² IM is given 24 hours after methotrexate completion 1
• The asparaginase depletes asparagine, which synergizes with methotrexate by preventing cellular rescue from methotrexate's effects 5
• Monitor for asparaginase-specific toxicities: coagulopathy, thrombosis, hyperglycemia, pancreatitis, and hepatotoxicity 1

Monitoring Requirements

Pre-Treatment Assessment

• CBC with differential, comprehensive metabolic panel including creatinine and liver function tests before each dose 2
• Ensure ANC >1000/μL before proceeding, as lower baseline ANC correlates with increased toxicity 2
• BMI assessment is important, as lower BMI (<18.5) significantly increases toxicity risk 2

During and Post-Treatment

• Daily CBC monitoring for 3-5 days post-infusion to detect early pancytopenia 4
• Serum creatinine at 24 and 48 hours post-infusion to detect nephrotoxicity 6
• Maintain aggressive hydration at 125-150 mL/m²/hour starting 12 hours before and continuing 24-36 hours after methotrexate to prevent renal toxicity 6
• Urine alkalinization to pH >7.0 with sodium bicarbonate reduces methotrexate precipitation in renal tubules 6

Efficacy Context

• Capizzi methotrexate demonstrated superior outcomes compared to high-dose methotrexate (5 g/m²) in T-ALL patients up to age 30, but not in B-ALL 1
• The regimen achieves therapeutic effect through sustained intermediate concentrations rather than peak high concentrations 3
• Target steady-state concentration is ≥16 μM, as concentrations <16 μM are associated with 3-fold higher relapse risk 3

Common Pitfalls and Management

Toxicity Profile

• Combined toxicity incidence is 28.7% across all cycles, similar to high-dose methotrexate 2
• Mucositis occurs in 5.5% of cycles (significantly less than 14.6% with high-dose methotrexate) 2
• Male gender independently predicts higher toxicity risk 2
• Severe multiorgan toxicity can occur even after the first dose, requiring immediate recognition and leucovorin rescue 4

CNS Prophylaxis Gap

• Capizzi methotrexate produces relatively low CSF concentrations despite dose escalation 5
• Concurrent intrathecal methotrexate must be administered on weeks 1 and 3 of the 8-week interim maintenance cycle 1
• Failure to provide adequate CNS-directed therapy increases risk of isolated CNS relapse 5

Dose Modifications

• Do not reduce doses inappropriately, as this compromises efficacy 1
• If Grade 3-4 toxicity occurs, hold methotrexate until recovery to Grade ≤1, then resume at one dose level lower 2
• For patients with renal impairment (CrCl <60 mL/min), reduce initial dose by 50% and escalate more cautiously 1

Contraindications in This Population

• Active infection requires treatment delay until resolved 1
• Significant hepatic dysfunction (transaminases >5× ULN) mandates dose reduction or regimen change 1
• Pregnancy is an absolute contraindication; ensure effective contraception throughout treatment 1